| Application no. and date | 10185782.9 (espacenet) (Federated) (European Patent Register), 20040421 | | Patent/reg. no. and date | DK/EP 2316456, 20170614 | | Publication date | 20110504 | | Priority no. and date | US 466838 P, 20030429 | | EP pub. no. and date |
EP 2316456 20110504 | | Effective date | | | Applicant/owner | Orexigen Therapeutics, Inc., 3344 North Torrey Pines Court, Suite 200
La Jolla, CA 92037, US | | Applicant ref. no. | 62373DK01 | | Inventor | COWLEY, Michael Alexander, 6724 SE 19th Avenue
Portland, OR 97202, US,
WEBER, Eckard,
4040, Miller Street
San Diego, CA 92130, US | | Representative | Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, DK | | Opponent | | | IPC Class | A61K 31/137 (2006.01) , A61K 31/485 (2006.01) , A61K 45/06 (2006.01) , A61P 3/04 (2006.01) | | Title | Sammensætninger til at påvirke vægttab omfattende en opioidantagonist og bupropion | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | CA 2017 00062 | | Status | Udløbet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
